Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor

Transplantation

Volumn 85, Issue 3, 2008, Pages 486-490

  Durrbach, Antoine ^a   Rostaing, Lionel ^b   Tricot, Leila ^c   Ouali, Nacera ^d   Wolf, Philippe ^e   Pouteil Noble, Claire ^f   Kessler, Michele ^g   Viron, Beatrice ^h   Thervet, Eric ^c  

^a BICÊTRE HOSPITAL   (France)

^b CHU RANGUEIL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HÔPITAL TENON   (France)

^e HÔPITAL DE HAUTEPIERRE   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g CHU NANCY BRABOIS   (France)

^h BICHAT HOSPITAL   (France)

Author keywords

Delayed graft function; Expanded criteria donor; Renal transplantation; Sirolimus

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DONOR; DOSE RESPONSE; GRAFT REJECTION; HUMAN; KIDNEY; KIDNEY TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PILOT STUDY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MIDDLE AGED; PILOT PROJECTS; SIROLIMUS; TISSUE DONORS;

EID: 41149159682     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318160d3c9     Document Type: Article

References (21)

1. Ramos E, Aoun S, Harmon WE. Expanding the donor pool: Effect on graft outcome. J Am Soc Nephrol 2002; 13: 2590.
2. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281.
3. Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2002; 2: 701.
4. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 1110.
5. DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507.
6. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.
7. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560.
8. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436.
9. Oberbauer R, Kreis H, Johnson RW, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364.
10. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755.
11. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416.
12. McTaggart RA, Tomlanovich S, Bostrom A, Roberts JP, Feng S. Comparison of outcomes after delayed graft function: Sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens. Transplantation 2004; 78: 475.
13. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 2004; 15: 228.
14. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
15. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
16. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 461.
17. Giessing M, Budde K. Sirolimus and lymphocele formation after kidney transplantation: An immunosuppressive medication as cofactor for a surgical problem? Nephrol Dial Transplant 2003; 18: 448.
18. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804.
19. Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S. Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 2003; 76: 1594.
20. Loverre A, Ditonno P, Crovace A, et al. Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: Differential modulation by rapamycin. J Am Soc Nephrol 2004; 15: 2675.
21. Pallet N, Thervet E, Le Corre D, et al. Rapamycin inhibits human renal epithelial cell proliferation: Effect on cyclin D3 mRNA expression and stability. Kidney Int 2005; 67: 2422.